Purpose of this Study
We are doing this study to find out if certain experimental drug combinations are safe and effective options for people who have recurrent or persistent endometrial cancer (cancer that has come back after treatment or does not respond to treatment).
Who Can Participate?
Eligibility
Adults ages 18+ who:<ul>
<li>Are diagnosed with endometrial cancer</li>
<li>Did not respond to previous treatment or had their cancer return after treatment</li>
<li>Have not received more than 2 lines of previous therapy (can include chemoradiation, chemotherapy and/or biologic therapy, or maintenance/consolidation therapy - hormonal therapies like aromatase inhibitors or tamoxifen do not count as a line of therapy)</li></ul>
For more information about this study, contact the study team at <a href= "mailto: william.s.andrews@duke.edu">william.s.andrews@duke.edu.</a>
<li>Are diagnosed with endometrial cancer</li>
<li>Did not respond to previous treatment or had their cancer return after treatment</li>
<li>Have not received more than 2 lines of previous therapy (can include chemoradiation, chemotherapy and/or biologic therapy, or maintenance/consolidation therapy - hormonal therapies like aromatase inhibitors or tamoxifen do not count as a line of therapy)</li></ul>
For more information about this study, contact the study team at <a href= "mailto: william.s.andrews@duke.edu">william.s.andrews@duke.edu.</a>
Age Range
18-110
Sex/Genders
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
If you choose to join this study, you will be assigned a specific study regimen based on specific biomarkers we find in a sample of your tumor. Depending on our findings, you will get one of the following study drug regimens:<ul>
<li>Atezolizumab + Bevacizumab doublet</li>
<li>Atezolizumab + Ipatasertib doublet</li>
<li>Atezolizumab + Talazoparib doublet</li>
<li>Atezolizumab + Trastuzumab Emtansine</li>
<li>Atezolizumab and Tiragolumab</li>
<li>Inavolisib + Letrozole doublet</li></ul>
<li>Atezolizumab + Bevacizumab doublet</li>
<li>Atezolizumab + Ipatasertib doublet</li>
<li>Atezolizumab + Talazoparib doublet</li>
<li>Atezolizumab + Trastuzumab Emtansine</li>
<li>Atezolizumab and Tiragolumab</li>
<li>Inavolisib + Letrozole doublet</li></ul>
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
No
Spanish Materials Available
No
Study Details
Full Title
A Phase IB/II Multi-Cohort Study of Targeted Agents with Atezolizumab for Patients with Recurrent or Persistent Endometrial Cancer
Principal Investigator
Angeles
Secord
Protocol Number
PRO00107981
NCT ID
NCT04486352
Phase
I/II
Enrollment Status
Open to Enrollment